304am永利集团|·主頁(歡迎您)

Reliable Quality

Affordable Innovation

Name Indication Clinical Trial Phase Study Title
HX301
Solid Tumours
Phase I/II A Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Initial Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Patients With Locally Advanced/Metastatic Solid Tumors or Lymphoma
HLX14
Postmenopausal
Phase III A Randomized, Double-Blind, International Multicentre, Parallel-Controlled Phase III Clinical Study to Evaluate Recombinant Anti-RANKL Human Monoclonal Antibody Injection (HLX14) Versus Denosumab Injection (Prolia®) in Postmenopausal Women With Osteoporosis at High Risk of Fracture
HLX10+HLX07
Soild Tumours
phase II
HLX10+HLX07
Squamous Non-small-cell Lung Cancer
phase II A Randomized, Open-Label, Multicenter, Phase II Study of HLX07 (Anti-EGFR Antibody) In Combination With HLX10 (Anti-PD-1 Antibody) With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line Recurrent or Metastatic Squamous Non-Small Cell Lung Cancer.
HLX10+HLX07
Head and Neck Squamous Cell Carcinoma
phase II Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors
Baidu
sogou